TOTAL FEMORAL ENDOPROSTHETIC REPLACEMENT FOR BONE TUMOURS – A 25 YEAR EXPERIENCE

Abstract

Introduction: Total femoral endoprosthetic replacement can be used as an alternative to hip disarticulation following extensive tumour excision or in cases of more severe bone loss. To date there have been no long term studies on the oncological and functional outcome of patients who have had this procedure for malignant bone disease. We report our experience of over 25 years employing this procedure using a custom-made and modular total femoral endoprosthetic replacement.

Methods: This is a retrospective, single centre study of 27 patients who underwent consecutive total femoral replacement as a primary procedure between 1978 and 2005. Information was collected from the bone tumour database, medical records and clinic review. Outcome was assessed using the Musculoskeletal Tumour Society (MSTS) rating score, the Harris Hip Score (HHS) and the Oxford Knee Score (OKS).

Results: There were 15 males and 12 females, with a mean age of 30 years (5 to 65). The overall mean follow-up was 4.3 years (1 to 16.4) for all patients, 9.1 years (1 to 16.4) for the 7 patients who were alive at the time of this review, and 2.6 years (1 to 13) for the 20 patients who had died. 24 patients had primary malignant bone tumours of the femur and 3 had metastatic disease from a known primary elsewhere. 3 patients developed local recurrence, 1 patient developed new lung metastases. Mean MSTS score was 63% (19/30), mean HHS was 68/100 and mean OKS was 34/48.

Discussion: Total femoral replacement can be an effective alternative to hip disarticulation in patients with malignant bone disease. Good functional outcomes can be achieved without compromising survival.